QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NYSE:CVM

CEL-SCI (CVM) Stock Price, News & Analysis

$1.51
-0.08 (-5.03%)
(As of 04/16/2024 ET)
Today's Range
$1.50
$1.56
50-Day Range
$1.58
$3.08
52-Week Range
$1.04
$3.23
Volume
171,372 shs
Average Volume
305,750 shs
Market Capitalization
$81.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CVM stock logo

About CEL-SCI Stock (NYSE:CVM)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

CVM Stock Price History

CVM Stock News Headlines

CVM: Parallel Engagement on Four Fronts
Biden out June 13; Kamala won’t replace him?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
CEL-SCI (NYSE:CVM) Trading Down 3.9%
CVM CEL-SCI Corporation
Biden out June 13; Kamala won’t replace him?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
CEL-SCI Corporation Issues Letter to Shareholders
CVM Apr 2024 4.000 call
CVM: Fiscal Year 2023 in Review
CEL-SCI Corp CVM
CVM: NICE To Have Your Support
See More Headlines
Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
4/16/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-32,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.28 per share

Miscellaneous

Free Float
46,390,000
Market Cap
$80.97 million
Optionable
Optionable
Beta
1.29
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Geert R. Kersten Esq. (Age 65)
    Chief Executive & Financial Officer, Treasurer and Director
    Comp: $702.79k
  • Ms. Patricia B. Prichep (Age 73)
    Senior VP of Operations & Corporate Secretary
    Comp: $295.18k
  • Dr. Eyal Talor Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $351.88k
  • Dr. Daniel H. Zimmerman Ph.D. (Age 83)
    Senior Vice President of Research & Cellular Immunology
    Comp: $46.08k
  • Mr. John Cipriano (Age 82)
    Senior Vice President of Regulatory Affairs
    Comp: $246.97k

CVM Stock Analysis - Frequently Asked Questions

How have CVM shares performed in 2024?

CEL-SCI's stock was trading at $2.72 at the beginning of 2024. Since then, CVM shares have decreased by 44.5% and is now trading at $1.51.
View the best growth stocks for 2024 here
.

When is CEL-SCI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CVM earnings forecast
.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSE:CVM) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.14) earnings per share (EPS) for the quarter.

When did CEL-SCI's stock split?

Shares of CEL-SCI reverse split before market open on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of CEL-SCI?

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CVM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners